Professor Penelope D Ottewell

School of Medicine and Population Health

Professor of Cancer Biology

p.d.ottewell@sheffield.ac.uk
+44 114 215 9058

Office: GU21, The Medical School

Full contact details

Professor Penelope D Ottewell
School of Medicine and Population Health
Office: GU21
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

Professor Penelope (Penny) Ottewell was awarded her personal chair as Professor of Cancer Biology in the Mellanby Centre for Musculoskeletal Research in 2022. She has won multiple national and international awards for her work including an International Bone and Mineral Society Fellowship and is currently the holder of a Breast Cancer Now Patricia Swannell Dormancy and Late Recurrence award.

Penny’s work is focussed on the field of cancer metastasis with a particular emphasis on immune cell regulation and the bone microenvironment. Her work in this field is currently funded by AstraZeneca, Beyer, MRC, Breast Cancer Now and Yorkshire Cancer Research.

Penny works on the editorial board for multiple per reviewed journals, sits on the former NCRI Bone metastasis strategy working group and is a member of the Cancer and Bone Society Executive Committee. She is also a member of the grant review committees for Breast Cancer Now (UK) and The National Science Centre (Poland).

Current PhD opportunities

Preventing outgrowth of dormant breast cancer cells in bone

Research interests

My research is focused on advanced breast cancer with particular emphasis on bone metastasis. Primarily, this involves using a complement of in vitro and in vivo model systems to investigate the molecular alterations that are acquired by breast cancer cells causing them to metastases to bone.

I hypothesise that metastases are a result of a stepwise accumulation of genetic mutations and that distinct molecular alterations are required at the different stages in the metastatic process; molecules involved in intravasation are not those involved in tissue homing and colonisation.

The aims of my research are to identify specific molecular determinants involved in tumour cell intravasation, homing to bone and colonisation of the metastatic site and to use this information to develop and apply new therapies for the treatment of breast cancer bone metastasis.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Eyre R, Alférez DG, Santiago-Gómez A, Spence K, McConnell JC, Hart C, Simões BM, Lefley D, Tulotta C, Storer J , Gurney A et al (2019) Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nature Communications, 10(1), ---.

All publications

Journal articles

Lefley DV, Jones CG, Zhou J, Bryant HE, Collis SJ, Down JM, Brown JE & Ottewell PD (2025) ATM inhibition increases the anti-tumor efficacy of radium-223 (Ra-223) against prostate cancer bone metastasis in preclinical models. JBMR Plus, 9(10). View this article in WRRO
Puppo M, Croset M, Ceresa D, Valluru MK, Canuas Landero VG, Hernandez Guadarrama M, Iuliani M, Pantano F, Dawn Ottewell P & Clézardin P (2024) Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis. Breast Cancer Research, 26. View this article in WRRO
Morita M, Arshad F, Quayle LA, George CN, Lefley DV, Kalajzic I, Balsubramanian M, Cebe T, Reilly G, Bishop NJ & Ottewell PD (2024) Losartan alters osteoblast differentiation and increases bone mass through inhibition of TGFB signalling in vitro and in an OIM mouse model. Bone Reports, 22. View this article in WRRO
Zhou J & Ottewell PD (2024) The role of IL-1B in breast cancer bone metastasis. Journal of Bone Oncology, 46, 100608-100608.
Kwan A, Stark K, Allen R, Ottewell P & Muthana M (2024) An Overview of the Bench to Bedside Models of Breast Cancer in the Era of Cancer Immunotherapy. Medical Research Archives, 12(6).
Puppo M, Valluru MK, Croset M, Ceresa D, Iuliani M, Khan A, Wicinski J, Charafe-Jauffret E, Ginestier C, Pantano F , Ottewell PD et al (2023) MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness. British Journal of Cancer, 129(5), 754-771. View this article in WRRO
Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I (2023) The CDK4/6 inhibitor palbociclib inhibits estrogen-positive and triple negative breast cancer bone metastasis in vivo. Cancers, 15(8). View this article in WRRO
Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al (2022) Macrophage delivered HSV1716 is active against triple negative breast cancer. Future Pharmacology, 2(4), 444-459. View this article in WRRO
Zhou J, Down JM, George CN, Murphy J, Lefley DV, Tulotta C, Alsharif MA, Leach M & Ottewell PD (2022) Novel methods of targeting IL-1 signalling for the treatment of breast cancer bone metastasis. Cancers, 14(19). View this article in WRRO
Zhou J, Tulotta C & Ottewell PD (2022) IL-1β in breast cancer bone metastasis. Expert Reviews in Molecular Medicine, 24.
Canuas-Landero VG, George CN, Lefley DV, Corness H, Muthana M, Wilson C & Ottewell PD (2021) Oestradiol contributes to differential antitumour effects of adjuvant zoledronic acid observed between pre- and post-menopausal women. Frontiers in Endocrinology, 12.
Quayle LA, Spicer A, Ottewell PD & Holen I (2021) Transcriptomic profiling reveals novel candidate genes and signalling programs in breast cancer quiescence and dormancy. Cancers, 13(16). View this article in WRRO
Tulotta C, Lefley DV, Moore CK, Amariutei AE, Spicer-Hadlington AR, Quayle LA, Hughes RO, Ahmed K, Cookson V, Evans CA , Vadakekolathu J et al (2021) IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. npj Breast Cancer, 7(1).
Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB & Holen I (2021) Bone metastasis : mechanisms, therapies and biomarkers. Physiological Reviews, 101(3), 797-855. View this article in WRRO
Canuas-Landero V, George C, Lefley D, Wilson C & Ottewell P (2021) Interactions between oestradiol and zoledronic acid in the bone microenvironment; physiological changes altering metastatic potential of breast cancer cells in pre- and post-menopausal women. Bone Reports, 14. View this article in WRRO
George C, Lefley D, Canuas-Landero V, Tulotta C, Corness H, Wilson C, Muthana M & Ottewell P (2021) Differential effects of zoledronic acid and oestrogen on anti-cancer immunity. Bone Reports, 14, 101024-101024.
Hughes R, Chen X, Cowley N, Ottewell PD, Hawkins RJ, Hunter KD, Hobbs JK, Brown NJ & Holen I (2021) Osteoblast-derived paracrine and juxtacrine signals protect disseminated breast cancer cells from stress. Cancers, 13(6). View this article in WRRO
Ottewell PD & Lawson MA (2021) Advances in murine models of breast cancer bone disease. Journal of Cancer Metastasis and Treatment, 7.
Al-Sahaf S, Hendawi NB, Ollington B, Bolt R, Ottewell PD, Hunter KD & Murdoch C (2021) Increased abundance of tumour-associated neutrophils in HPV-negative compared to HPV-positive oropharyngeal squamous cell carcinoma is mediated by IL-1R signalling. Frontiers in Oral Health, 2. View this article in WRRO
Kwan A, Winder NJ, Atkinson E, Al-Janabi HH, Allen RJ, Hughes R, Moamin MR, Louie R, Evans D, Hutchinson M , Capper DT et al (2020) Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.. Mol Cancer Ther.
George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson C & Ottewell P (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology, 25. View this article in WRRO
Bishop RT, Marino S, Carrasco G, Li B, Allen RJ, Sparatore A, Ottewell PD, Mollat P, Sims AH, Capulli M , Wang N et al (2020) Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 488, 27-39.
Ran R, Harrison H, Syamimi Ariffin N, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Mason SM, Blyth K , Holen I et al (2020) A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells. Oncogene, 39(12), 2624-2637. View this article in WRRO
Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, Eyre R, Alférez D, Wilkinson JM, Holen I , Clarke RB et al (2019) Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts. Breast Cancer Research, 21(1), ---.
Eyre R, Alférez DG, Santiago-Gómez A, Spence K, McConnell JC, Hart C, Simões BM, Lefley D, Tulotta C, Storer J , Gurney A et al (2019) Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nature Communications, 10(1), ---.
Ottewell P & Wilson C (2019) Bone-targeted agents in breast cancer : do we now have all the answers?. Breast Cancer: Basic and Clinical Research, 13.
Allocca G, Hughes R, Wang N, Brown HK, Ottewell PD, Brown NJ & Holen I (2019) The bone metastasis niche in breast cancer– potential overlap with the haematopoietic stem cell niche in vivo. Journal of Bone Oncology, 17. View this article in WRRO
Bishop RT, Marino S, de Ridder D, Allen RJ, Lefley DV, Sims AH, Wang N, Ottewell PD & Idris AI (2019) Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.. Cancer Letters, 450, 76-87. View this article in WRRO
Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter-Howard F, Wilkinson JM, Spicer-Hadlington AR, Liu X , Bradbury S et al (2019) Endogenous production of IL-1B by breast cancer cells drives metastasis and colonisation of the bone microenvironment. Clinical Cancer Research, 25(9), 2769-2782. View this article in WRRO
Ran R, Harrison H, Ariffin NS, Ayub R, Pegg HJ, Deng W, Mastro A, Ottewell PD, Fowles AM, Blyth SMMK , Holen I et al (2019) RUNX/CBFβ transcription factor complexes promote the phenotypic plasticity of metastatic breast cancer cells.
Al-Sahaf S, Hunter KD, Bolt R, Ottewell PD & Murdoch C (2019) The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer. International Journal of Cancer, 144(2), 334-344. View this article in WRRO
Quayle LA, Ottewell PD & Holen I (2018) Chemotherapy resistance and stemness in mitotically quiescent human breast cancer cells identified by fluorescent dye retention. Clinical & Experimental Metastasis, 35(8), 831-846. View this article in WRRO
Brown HK, Allocca G, Ottewell PD, Wang N, Brown NJ, Croucher PI, Eaton CL & Holen I (2018) Parathyroid Hormone (PTH) Increases Skeletal Tumour Growth and Alters Tumour Distribution in an In Vivo Model of Breast Cancer. International Journal of Molecular Sciences, 19(10). View this article in WRRO
Tulotta C & Ottewell PD (2018) The role of IL-1B in breast cancer bone metastasis. Endocrine-Related Cancer, 25(7), R421-R434. View this article in WRRO
Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M & Ottewell PD (2017) Erratum to: Loss of plakoglobin promotes cell-cell contact, increased invasion and breast cancer cell dissemination in vivo.. Breast Cancer Research, 19.
Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE & Ottewell P (2016) IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget, 7, 75571-75584. View this article in WRRO
Ottewell PD (2016) The role of osteoblasts in bone metastasis. Journal of Bone Oncology, 5(3), 124-127. View this article in WRRO
Ottewell P, Brown H, Allocca G, Haider MT, Brown N & Holen I (2016) The bone microenvironment as a master regulator of tumour cell dormancy in breast cancer - evidence from novel in vivo models. European Journal of Cancer, 61, S74-S75.
Wright LE, Ottewell PD, Rucci N, Peyruchaud O, Pagnotti GM, Chiechi A, Buijs JT & Sterling JA (2016) Murine models of breast cancer bone metastasis. BoneKEy Reports, 5(804). View this article in WRRO
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE , Selby PJ et al (2016) CAPG and gipc1: Breast cancer biomarkers for bone metastasis development and treatment. Journal of the National Cancer Institute, 108(4). View this article in WRRO
Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL & Ottewell PD (2016) Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clinical & Experimental Metastasis, 33(3), 211-224. View this article in WRRO
Wang N, Reeves KJ, Brown HK, Fowles ACM, Docherty FE, Ottewell PD, Croucher PI, Holen I & Eaton CL (2015) The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 34. View this article in WRRO
Ottewell PD, Wang N, Brown HK, Fowles CA, Croucher PI, Eaton CL & Holen I (2015) OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. International Journal of Cancer, 137(4), 968-977. View this article in WRRO
Quayle L, Ottewell PD & Holen I (2015) Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer. CURRENT CANCER DRUG TARGETS, 15(6), 469-480.
Holen I, Nutter F, Wilkinson JM, Evans CA, Avgoustou P & Ottewell PD (2015) Human breast cancer bone metastasis in vitro and in vivo: a novel 3D model system for studies of tumour cell-bone cell interactions.. Clinical & Experimental Metastasis, 32(7), 689-702. View this article in WRRO
Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, Ottewell PD, Holen I, Croucher PI & Eaton CL (2015) Mitotic quiescence, but not unique "stemness," marks the phenotype of bone metastasis-initiating cells in prostate cancer. FASEB Journal, 29(8), 3141-3150. View this article in WRRO
Ottewell PD, O'Donnell L & Holen I (2015) Molecular alterations that drive breast cancer metastasis to bone.. Bonekey Reports, 4, 643. View this article in WRRO
Wilson C, Ottewell P, Coleman RE & Holen I (2015) The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.. BMC Cancer, 15.
Wang N, Docherty FE, Brown HK, Reeves KJ, Fowles ACM, Ottewell PD, Dear TN, Holen I, Croucher PI & Eaton CL (2014) Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models.. J Bone Miner Res, 29(12), 2688-2696.
Ottewell PD, Wang N, Meek J, Fowles CA, Croucher PI, Eaton CL & Holen I (2014) Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocrine Related Cancer, 21(5), 769-781.
Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI, Eaton CL & Holen I (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.. Clin Cancer Res, 20(11), 2922-2932.
David M, Machuca-Gayet I, Kikuta A, Ottewell PD, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Vales RJ , Jurdic P et al (2014) Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.. Journal of Biological Chemistry, 10(289), 6551-6564.
Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, Coleman RE, Westbrook JA, Selby PJ, Brown JE & Ottewell PD (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line.. Endocr Relat Cancer, 21(2), 327-341.
David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Vales RL , Jurdic P et al (2014) Lysophosphatidic Acid Receptor Type 1 (LPA1) Plays a Functional Role in Osteoclast Differentiation and Bone Resorption Activity. Journal of Biological Chemistry, 289(10), 6551-6564.
Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, Ottewell PD & Holen I (2013) Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.. Cell Oncol (Dordr), 36(6), 505-514.
Holen I, Wang N, Reeves KJ, Fowles AM, Croucher PI, Eaton CL & Ottewell PD (2012) Abstract PD07-08: Zoledronic acid specifically inhibits development of bone metastases in the post-menopausal setting – evidence from an in vivo breast cancer model. Cancer Research, 72(24_Supplement).
Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2012) A single administration of combination therapy inhibits breast tumour progress bone and modifies both osteoblasts and osteoclasts. Journal of Bone Oncology, 1(2), 47-56.
Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV, Barbaric I, Jones M & Ottewell PD (2012) Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo.. Breast Cancer Res, 14(3), R86.
Brown HK, Ottewell PD, Evans CA & Holen I (2012) Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.. Clin Exp Metastasis, 29(8), 927-938.
Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE & Holen I (2012) Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.. Breast Cancer Res Treat, 133(2), 523-536.
Ottewell PD, Whitworth J, Cross SS, Nutter FH & Holen I (2011) P2-01-20: Reduced Plakoglobin Expression Increases the Metastatic Potential of Breast Cancer Cells.. Cancer Research, 71(24_Supplement).
Ottewell PD (2011) Meeting report from the 10th international conference on cancer-induced bone disease. IBMS BoneKEy, 8(1), 41-45.
Brown HK, Ottewell PD, Coleman RE & Holen I (2011) The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.. J Cell Mol Med, 15(3), 501-513.
Syddall SP, Ottewell PD & Holen I (2010) Combined therapies of bone disease with bisphosphonates.. Curr Pharm Des, 16(27), 2988-2997.
Ottewell PD (2010) Effects of gastrin and its precursor peptides upon intestinal epithelia..
Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE & Holen I (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.. Int J Cancer, 126(2), 522-532.
Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE & Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.. Mol Cancer Ther, 8(10), 2821-2832.
Ottewell PD, Lefley DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. Cancer Research, 69(2_Supplement), 2151-2151.
Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE & Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.. J Natl Cancer Inst, 100(16), 1167-1178.
Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P & Holen I (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.. Clin Cancer Res, 14(14), 4658-4666.
Mönkkönen H, Ottewell PD, Kuokkanen J, Mönkkönen J, Auriola S & Holen I (2007) Zoledronic acid-induced IPP/ApppI production in vivo.. Life Sci, 81(13), 1066-1070.
Ottewell PD, Duckworth CA, Varro A, Dimaline R, Wang TC, Watson AJM, Dockray GJ & Pritchard DM (2006) Gastrin increases murine intestinal crypt regeneration following injury.. Gastroenterology, 130(4), 1169-1180.
Ottewell PD, Coleman RE & Holen I (2006) From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.. Breast Cancer Res Treat, 96(2), 101-113.
Keen H, Dekker B, Lyons S, Disley L, Hastings D, Reader A, Ottewell PD, Watson A & Zweit J (2005) Imaging apoptosis in vivo using 124I-annexin V and PET.. Nucl Med Biol, 4(32), 395-402.
Dekker B, Keen H, Lyons S, Disley L, Hastings D, Reader A, Ottewell PD, Watson A & Zweit M (2005) MBP-annexin V radiolabeled directly with iodine-124 can be used to image apoptosis in vivo using PET.. Nucl Med Biol, 3(32), 241-252.
Ottewell PD, Varro A, Dockray GJ, Kirton CM, Watson AJM, Wang TC, Dimaline R & Pritchard DM (2005) COOH-terminal 26-amino acid residues of progastrin are sufficient for stimulation of mitosis in murine colonic epithelium in vivo.. Am J Physiol Gastrointest Liver Physiol, 288(3), G541-G549.
Ottewell PD, Watson AJM, Wang TC, Varro A, Dockray GJ & Pritchard DM (2003) Progastrin stimulates murine colonic epithelial mitosis after DNA damage.. Gastroenterology, 124(5), 1348-1357.
Pritchard DM, Ottewell PD, Watson AJM, Wang TC & Dockray GJ (2002) Progastrin Stimulates Murine Colonic Epithelial Mitosis after Dna Damage. Clinical Science, 103(s47), 43P-43P.
Ottewell PD, Watson AJM, Wang TC, Dockray GJ & Pritchard DM (2002) Progastrin stimulates murine colonic epithelial mitosis after DNA damage. GUT, 50, A93-A93.
Pritchard D, Ottewell PD, Watson AJM, Wang TC & Dockray GJ (2002) Progastrin stimulates murine colonic epithelial mitosis after DNA damage. GASTROENTEROLOGY, 122(4), A684-A684.
Marshman E, Ottewell PD, Potten CS & Watson AJ (2001) Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine.. J Pathol, 195(3), 285-292.
MCMICHAEL D, DAVIES A, MARSHMAN E, OTTEWELL P, JENKINS J & WATSON A (2001) Gene array and knockout mouse analysis of VP-16 induced apoptosis in the murine small intestine. Gastroenterology, 120(5), A660-A660.
McMichael DP, Davies A, Marshman E, Ottewell PD, Jenkins JR & Watson AJM (2001) Gene array and knockout mouse analysis of VP-16 induced apoptosis in the murine small intestine. GASTROENTEROLOGY, 120(5), A660-A660.
Eksteen JA, Smith JL, Tselepis C, Perry I & Harrison RF (2001) 226. IMMUNE RESPONSES IN BARRETT'S METAPLASIA. Gut, 48(suppl 1), A60.2-A64.
Hou S-Y, Macfarlane SC, Gómez Torijano A, Kim HR, Rosier M, Dobra K, Ottewell PD & Gad AKB () Cancer-Associated Fibroblasts Move and Interact More with Triple-Negative Breast Cancer Cells and Stimulate Their Proliferation in a Hyaluronan-Dependent Manner. Cells, 14(21), 1663-1663.
Haider M-T, Ottewell PD, Brown NJ, Lefley DV & Holen I () Peripheral tumour re-growth following combination therapy - role of the bone microenvironment. Bone Abstracts.
Bradbury S, Rennicks S, Evans A, del CBM, Holen I & Ottewell P () Blocking IL-1R signalling inhibits breast cancer growth and bone metastases by altering the tumour microenvironment. Bone Abstracts.
Ottewell PD () 11th International Conference on Cancer-Induced Bone Disease. IBMS BoneKEy, 9.

Book chapters

Zhou J, Lefley D & Ottewell P (2025) Mouse Models of Breast Cancer Bone Metastasis, Methods in Molecular Biology (pp. 399-421). Springer US
Holen I, Saleh L, Ottewell PD & Lawson MA (2022) In vivo models used in studies of bone metastases, Bone Cancer (pp. 35-53). Elsevier
George C, Michael N & Ottewell PD (2022) Bone, a fertile soil for tumor development, Bone Cancer (pp. 121-128). Elsevier
Ottewell PD & Quayle LA (2019) Tumor dormancy in the bone, Reference Module in Biomedical Sciences Elsevier View this article in WRRO
Tulotta C, Groenewoud A, Snaar-Jagalska BE & Ottewell P (2019) Animal Models of Breast Cancer Bone Metastasis, Methods in Molecular Biology (pp. 309-330). Springer New York

Conference proceedings

Lefley D, Jones C, Danson S, Bryant H, Collis S, Brown J & Ottewell P (2023) Addition of ATM Inhibitors to Radium223 Reduces Prostate Cancer Bone Metastases In Vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 214-215)
Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538)
Tulotta C, Moore CK, Lefley DV, Amariutei AE, Ahmed K, Spicer-Hadlington AR & Ottewell PD (2020) Inhibition of breast cancer bone metastasis through Interleukin-1B regulated tumour-associated innate immune response. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 538-539)
Bishop N, Kalajzic I, Arshad F, Lefley D, Gossiel F & Ottewell P (2019) Losartan reduces circulating TGFb and CTX and increases vertebral bone mass in the OIM mouse. Bone Abstracts, Vol. 7. Salzburg, Austria, 22 June 2019 - 22 June 2019. View this article in WRRO
Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Cancer Research, Vol. 79(13_Supplement)
Moamin MR, Monk P, Cox A, Ottewell P, Saint-Pol J, Rubinstein E & Muthana M (2019) Abstract LB-036: Tetraspanin 5 expressing macrophages promote mammary tumor growth. Tumor Biology
Ottewell PD, Lefley DV, Freeman K, Gregory WM, Hanby AM, Spicer-Hadlington AR, Liu X, Bradbury SM, Hambley L, Allocca G , Cookson V et al (2019) Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironment. Cancer Research, Vol. 79(4_Supplement)
Hughes R, Ottewell P, Hobbs J, Holen I & Brown NJ (2019) Breast Cancer Metastasis to Bone: The Role of the Perivascular Niche in Regulating Tumour Cell Dormancy. JOURNAL OF VASCULAR RESEARCH, Vol. 56 (pp 17-18)
(2018) 1st UK Interdisciplinary Breast Cancer Symposium—15th–16th January 2018. Breast Cancer Research and Treatment, Vol. 167(1) (pp 309-405)
Lefley D, Nutter F, Brown H, Tulotta C, Eyre R, Clarke R, Alferez D, Wilkinson M, Holen I & Ottewell P (2017) Human specific models for studying ER plus ve and ER- ve breast cancer bone metastasis. Clinical and Experimental Metastasis , Vol. 34(8) (pp 516-516). Berlin, Germany , 27 November 2017 - 27 November 2017. View this article in WRRO
Quayle L, Park S, McDonnell DP, Ottewell PD & Holen I (2017) Abstract P3-07-14: Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells. Cancer Research, Vol. 77(4_Supplement)
Eyre R, Alferez D, Santiago-Gomez A, Spence K, McConnell J, Simoes B, Hart C, Lefley D, Tulotta C, Gurney A , Howell S et al (2017) Targeting IL-1β-Wnt signalling to prevent breast cancer colonisation in the bone microenvironment. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 34(8) (pp 493-493)
Tulotta C, Lefley D, Liu X, Spicer-Hadlington A, Hamley L, Cookson V, Allocca G & Ottewell P (2017) IL-1B signalling regulates breast cancer bone metastasis. CLINICAL & EXPERIMENTAL METASTASIS, Vol. 34(8) (pp 516-516)
Ottewell P, Brown H, Allocca G, Haider MT, Brown N & Holen I (2016) The bone microenvironment as a master regulator of tumour cell dormancy in breast cancer - evidence from novel in vivo models. EUROPEAN JOURNAL OF CANCER, Vol. 61 (pp S74-S75)
Byrne M, Ottewell PD, Holen I, Sanderson T & Cross SS (2012) The Use of p63 in Distinguishing In Situ and Invasive Tumour in the PyMT Mouse Model of Breast Cancer. JOURNAL OF PATHOLOGY, Vol. 228 (pp S38-S38)
Brown HK, Ottewell PD, Evans CA, Coleman RE & Holen I (2011) Early intervention with a single dose of doxorubicin followed by zoledronic acid induces sustained inhibition of breast cancer-induced bone disease in a mouse model. BONE, Vol. 48 (pp S255-S255)
Ottewell PD, Whitworth J & Holen I (2011) THE ROLE OF PLAKOGLOBIN IN THE INITIATION OF BREAST CANCER METASTASES. ANNALS OF ONCOLOGY, Vol. 22 (pp 32-32)
Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
Ottewell PD, Whitworth J & Holen I (2011) THE ROLE OF PLAKOGLOBIN IN THE INITIATION OF BREAST CANCER METASTASES. ANNALS OF ONCOLOGY, Vol. 22 (pp 32-32)
Ottewell PD, Brown H, Rogers TL, Lefley DV, Evans AC, Wind N, Cross SS, Brown N, Coleman R & Holen I (2011) PREVENTION OF SPONTANEOUS MAMMARY TUMOUR GROWTH BY SEQUENTIAL ADMINISTRATION OF DOXORUBICIN AND ZOLEDRONIC ACID IN AN IMMUNOCOMPETENT MOUSE MODEL. ANNALS OF ONCOLOGY, Vol. 22 (pp 29-29)
Wind NS, Brown H, Ottewell PD, Sadej R, Romanska H, Berditchevski F & Holen I (2011) Does differential expression of CD151 affect the ability of beast cancer cells to establish tumours in bone?. BONE, Vol. 48(1) (pp S45-S45)
Brown HK, Ottewell PD, Evans CA, Coleman RE & Nolen I (2011) Combination vs single agent treatment: The effects of zoledronic acid +/- doxorubicin on breast tumour growth in bone prior to development of osteolytic bone disease. BONE, Vol. 48(1) (pp S41-S41)
Ottewell PD, Brown H, Evans CA, Wind NS, Brown NJ, Coleman RE & Holen I (2011) First evidence for anti-tumour effects of doxorubicin and zoledronic acid from an immunocompetent mouse model. BONE, Vol. 48(1) (pp S42-S42)
Westbrook JA, Peng J, Cairns DA, Ottewell PD, Holen I, Coleman RE, Selby PJ, Banks RE & Brown JE (2011) Towards biomarkers of bone-metastasis using cellular proteomics. BONE, Vol. 48(1) (pp S33-S33)
Brown HK, Ottewell PD, Evans CA & Holen I (2011) Changes in osteoblast and osteoclast number rely on direct contact with breast cancer cells - Evidence from a longitudinal study of bone metastasis. BONE, Vol. 48(1) (pp S40-S41)
Holen I, Ottewell PD & Coleman RE (2010) Abstract P6-14-03: Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy — Emerging Evidence of Anti-Tumour Effects Outside Bone. Cancer Research, Vol. 70(24_Supplement)
Ottewell PD, Lefely DV, Cross SS, Coleman RE & Holen I (2010) Sustained inhibition of tumour growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid. BONE, Vol. 47 (pp S317-S317)
Brown HK, Ottewell PD, Lefely DV, Coleman RE & Holen I (2010) Effects of doxorubicin followed by zoledronic acid on early, medium and late stage breast tumour growth in bone. BONE, Vol. 47 (pp S318-S319)
Woodward J, Holen I, Lefley D, Ottewell P & Buttle D (2010) Breast cancer-bone marrow stromal cell interactions modify expression of proteolytic enzymes and regulators of bone turnover. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 91(2) (pp A45-A46)
Ottewell PD, Leftey DV, Coleman RE & Holen I (2009) Evaluation of the molecular mechanisms for the sequence-dependent, synergistic anti-tumour effects of doxorubicin and zoledronic acid in breast cancer.. CANCER RESEARCH, Vol. 69(2) (pp 200S-201S)
Ottewell P, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell cycle arrest in sub-cutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. European Journal of Cancer Supplements, Vol. 6(9) (pp 18-18)
Ottewell PD, Lefley DV, Coleman RE & Holen I (2008) Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S41)
Lefley DV, Holen I, Coleman RE & Ottewell PD (2008) Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid. BREAST CANCER RESEARCH, Vol. 10 (pp S40-S40)
Ottewell P, Croucher P & Holen I (2008) P1. Breast cancer cells cause a reduction in osteoblast number – An early event in the development of osteolytic bone lesions. Cancer Treatment Reviews, Vol. 34 (pp 12-12)
Ottewell P, Coleman R & Holen I (2008) P18. Mechanisms of apoptosis and cell cycle arrest in intra-tibial breast tumours treated sequentially with doxorubicin followed by zoledronic acid. Cancer Treatment Reviews, Vol. 34 (pp 19-19)
Woodward J, Lefley D, Cross N, Ottewell PD, Buttle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, Vol. 88(6) (pp A97-A97)
Ottewell PD, Deux B, Monkkonen H, Cross SS, Coleman RE, Clezardin P & Holen I (2007) Differential effects of doxorubicin and zoledronic acid on intra-osseous vs extra-osseous breast tumour growth in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 106 (pp S39-S39)
Ottewell PD, Deux B, Monkkonen H, Coleman RE, Clezardin P & Holen I (2007) Differential effect of doxorubicin and zoledronic acid on intra-osseous vs extra osseous breast tumour growth in vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1111-1111)
Woodward JKL, Lefley DV, Cross NA, Ottewell PD, Battle DJ, Coleman RE & Holen I (2007) Tumour cell-bone marrow stromal cell interactions modify expression of cathepsin K, ADAMTS-15, TIMP-3 and osteoprotegerin (OPG). JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1142-1143)
Van Pozanki C, Otterwell P, Cross S, Hudis C, Coleman RE & Holen I (2007) Osteoprotegerin (OPG) expression in breast tumors and bone metastases. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, Vol. 22(1) (pp 83-84)
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo. BREAST CANCER RESEARCH, Vol. 8 (pp S17-S17)
Cross SS, Ottewell P, Swinscoe M, Majeed AW & Holen I (2006) Osteoprotegerin is strongly expressed in the intratumoural endothelial cells of gastrointestinal carcinomas. JOURNAL OF PATHOLOGY, Vol. 208 (pp 9A-9A)
Van Poznak C, Ottewell P, Cross S, Hudis C, Coleman RE & Holen I (2006) Osteoprotegerin (OPG) expression in breast tumours and bone metastases. Bone, Vol. 38(3) (pp 31-32)
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of cytotoxic drugs and anti-resorptive agents in vitro and in vivo.. BREAST CANCER RESEARCH AND TREATMENT, Vol. 100 (pp S290-S290)
Ottewell PD, Jones M, Coleman RE & Holen I (2006) Synergistic effects of zoledronic acid and doxorubicin in breast cancer models in vivo. CANCER TREATMENT REVIEWS, Vol. 32 (pp S30-S30)
Duckworth CA, Ottewell PD, Dimaline R, Varro A & Pritchard DM (2005) Hypergastrinaemia reduces the severity of dextran sulphate sodium induced colitis and 5-fluorouracil induced mucositis in mice. GUT, Vol. 54 (pp A98-A98)
Duckworth CA, Ottewell PD, Varro A, Dimaline R & Pritchard DM (2005) Hypergastrinaemia reduces the severity of dextran sulphate sodium induced colitis and 5-fluorouracil induced intestinal mucositis in mice.. GASTROENTEROLOGY, Vol. 128(4) (pp A203-A203)
Ottewell PD, Watson AJ, Varro A & Pritchard DM (2005) Radiation induces gastrin-CCKB receptor expression in IEC-6 and IEC-18 intestinal epithelial cells. GUT, Vol. 54 (pp A88-A88)
Przemeck SMC, Ottewell PD, Watson AJM & Pritchard DM (2005) Radiation induces p53 dependent apoptosis in the proliferative zone of mouse gastric epithelium. GUT, Vol. 54 (pp A88-A88)
Ottewell PD, Varro A, Watson AJM, Dimaline R, Dockray GJ & Pritchard DM (2004) Progastrin stimulates murine colonic epithelial mitosis after DNA damage in the absence of murine amidated gastrin. GASTROENTEROLOGY, Vol. 126(4) (pp A272-A272)
Davies A, Ottewell P, McNamara A, Jenkins JR & Watson AJM (2004) Etoposide induced p53-dependent gene expression in the GI tract: Analysis of BIRC3, a candidate gene. GASTROENTEROLOGY, Vol. 126(4) (pp A546-A546)
Ottewell PD, Watson A, Wang T, Dockray G & Pritchard M (2003) Progastrin stimulates murine colonic mitosis after DNA damage via the cyclin D1-cdk4 complex. GASTROENTEROLOGY, Vol. 124(4) (pp A100-A100)
Ottewell PD, Watson A, Wang T, Varro A, Dockray G & Pritchard M (2003) Elevated plasma concentrations of amidated gastrin cause increased crypt survival in murine intestinal epithelia after Gamma-radiation. GASTROENTEROLOGY, Vol. 124(4) (pp A610-A610)
Ottewell PD, Watson AJM, Wang TC, Varro A, Dockray GJ & Pritchard DM (2003) Elevated plasma concentrations of amidated gastrin cause increased crypt survival in murine intestinal epithelia after gamma radiation. GUT, Vol. 52 (pp A8-A8)
Davies A, Ottewell PD, McNamara A, Watson AJM & Jenkins JR (2003) P53 dependent differential expression analysis of etoposide induced stress in the murine small intestine. GUT, Vol. 52 (pp A36-A36)
Ottewell PD, Watson AJM, Wang TC, Dockray GJ & Pritchard DM (2003) Progastrin stimulates murine colonic mitosis after DNA damage via the cyclin D-cdk4 complex. GUT, Vol. 52 (pp A55-A55)
McMichael DP, Davies A, Marshman E, Ottewell PD, Jenkins JR & Watson AJM (2001) Knockout mouse and gene array analysis of etoposide induced apoptosis in the murine small intestine. GUT, Vol. 48 (pp A61-A62)
Arshad F, Lefley D, Madan S, Fernandes J, Bishop N & Ottewell P () Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children. Bone Abstracts

Preprints

Cabral S, Parsons J, Harrison H, Kedward T, Fullwood P, Spence K, Lefley DV, Barden D, Ferguson J, Watson J , Tsafou K et al (2023) Proteomics Identifies Osteomodulin as a Promoter of Breast Cancer Bone Metastasis via CDK1 Activation, Cold Spring Harbor Laboratory.
Shah KM, Tattersall L, Hussain A, Macfarlane SC, Williamson A, Acosta-Martin AE, Erler JT, Ottewell PD & Gartland A (2022) P2RX7 inhibition reduces breast cancer induced osteolytic lesions - implications for bone metastasis, Cold Spring Harbor Laboratory.

Research group

Diane Lefley - Research Technician
Claudia Tulotta - Post-doctoral Research Associate

Professional activities and memberships

British Association for Cancer Research, executive committee member
International Bone and Mineral Society, Young Investigators committee member.
Analytical and Cellular Pathology, editorial board
Open Journal of Oncology, editorial board